iTonic Holdings Ltd. ITOC
- Market cap
- $35.4M
- P/E
- —
Follow ITOC
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | 3.32 | 0.42 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | — | 6.45 | 32.00 |
High Price
|
|||
| — | — | — | — | — | — | — | 11 | 10 | 7 |
Employees
|
|||
| — | — | — | — | — | — | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | 1 | 1 | 0 | 1 |
Revenue
|
|||
| — | — | — | — | — | — | 82.11% | 74.90% | 85.05% | 62.60% |
Gross Margin
|
|||
| — | — | — | — | — | — | 0 | 0 | (1) | (5) |
EBT
|
|||
| — | — | — | — | — | — | 10.44% | (41.44%) | (142.53%) | (974.84%) |
EBT Margin
|
|||
| — | — | — | — | — | — | 0 | 0 | (1) | (5) |
Net Income
|
|||
| — | — | — | — | — | — | — | 0 | 0 | 0 |
Depreciation
|
|||
| — | — | — | — | — | — | 0.06 | 0.05 | 0.04 | 0.03 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | 0.01 | (0.02) | (0.05) | (0.32) |
Earnings/Sh
|
|||
| — | — | — | — | — | — | (0.01) | (0.01) | (0.06) | (0.20) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Capex/Sh
|
|||
| — | — | — | — | — | — | (0.01) | (0.01) | (0.06) | (0.20) |
Free CF/Sh
|
|||
| — | — | — | — | — | — | 0.05 | 0.03 | 0.49 | 0.51 |
Book Value/Sh
|
|||
| — | — | — | — | — | — | 12 | 12 | 13 | 16 |
Shares
|
|||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
PB Ratio
|
|||
| — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales
|
|||
| — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.66 |
EV/FCF
|
|||
| — | — | — | — | — | — | 0 | 0 | (1) | (3) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | — | 0 | 0 |
Capex
|
|||
| — | — | — | — | — | — | 0 | 0 | (1) | (3) |
FCF
|
|||
| — | — | — | — | — | — | 0 | (1) | 6 | 4 |
Working Cap'
|
|||
| — | — | — | — | — | — | — | — | 0 | 0 |
Total Debt
|
|||
| — | — | — | — | — | — | 0 | 0 | (6) | (3) |
Net Debt
|
|||
| — | — | — | — | — | — | 1 | 0 | 6 | 8 |
Sh' Equity
|
|||
| — | — | — | — | — | — | 0.00% | (15.98%) | (15.84%) | (64.45%) |
ROA
|
|||
| — | — | — | — | — | — | 3.55% | (243.26%) | (176.42%) | (60.67%) |
ROIC
|
|||
| — | — | — | — | — | — | 0.00% | (55.92%) | (20.35%) | (71.24%) |
ROE
|
|||
iTonic Holdings Ltd. peers in Medical Devices
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| ELUT Elutia Inc. | $36.8M | 0.7× | Compare |
| QTI QT Imaging Holdings, Inc. | $37.0M | 0.0× | Compare |
| BDMD Baird Medical Investment Holdings Limited | $32.9M | 0.0× | Compare |
| NSPR InspireMD, Inc. | $32.5M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| NSYS Nortech Systems Incorporated | $32.1M | 30.5× | Compare |
| PAVM PAVmed Inc. | $31.0M | 0.0× | Compare |
| SNWV Sanuwave Health Inc. | $41.7M | 3.0× | Compare |
| ARAY Accuray Incorporated | $27.8M | 0.0× | Compare |
iTonic Holdings Ltd. (ITOC) key facts
- iTonic Holdings Ltd. (ITOC) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
- iTonic Holdings Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $523,000.00, up 16.7% from fiscal 2024.
- iTonic Holdings Ltd. reported a net loss of $5.1 million, or a loss of $0.32 per share, for fiscal 2025.
- As of September 25, 2026, ITOC traded at $0.29, a market capitalization of $35.4 million.
- Return on equity was −71.2% and debt-to-equity 0.02.
iTonic Holdings Ltd. (ITOC) Latest News
15 Jul
iTonic Holdings Ltd updates on development of AI-powered cloud healthcare platform for nuclear medicine treatment planning, with potential future expansion into digital care delivery. Platform development efforts may moderately boost innovation positioning without confirmed launch or revenue impact.
23 Apr
Nasdaq granted iTonic Holdings Ltd. (ITOC) an additional 180-day extension to regain compliance with the minimum bid price rule. The extension prevents immediate delisting and provides time to address stock price compliance, moderately impacting market sentiment and short-term performance.
13 Jan
Pheton Holdings Ltd has announced a corporate name change and a new stock ticker symbol. The company will now operate under a different name, reflecting its strategic direction and branding efforts. The change in ticker symbol is expected to align with the new corporate identity, aiming to enhance market visibility and investor recognition. The name and ticker symbol change may moderately influence market perception and branding but is not expected to significantly alter the company's overall trajectory.
5 Dec
Pheton Holdings Ltd (PTHL) has successfully completed the acquisition of shares from iTonic Corporation, marking a significant step in its strategic growth plans. The transaction is expected to enhance PTHL's market position and expand its operational capabilities. Details regarding the financial terms of the acquisition were not disclosed, but the move aligns with PTHL's objectives to diversify its portfolio and strengthen its competitive edge in the industry. The acquisition is a major strategic move that could significantly alter PTHL's trajectory and investor sentiment.
1 Aug
Pheton Holdings Ltd (PTHL) has issued statements to clarify recent market activity and address misleading rumors that have circulated about the company. The management emphasizes its commitment to transparency and reassures stakeholders about the company's operational stability and future prospects. PTHL aims to mitigate any potential negative impact on investor sentiment and market performance caused by these rumors. Clarifications on misleading rumors can moderately influence investor sentiment and market perception.
17 Mar
Pheton Holdings Ltd. (NASDAQ:PTHL) surged by 81.7% last week, closing at $4.18, as investors engaged in bargain-hunting following a significant drop to $1.9 earlier in the month. The company, based in China, specializes in healthcare solutions for brachytherapy, a cancer treatment. Despite its recent gains, it ranks 7th among stocks with double- and triple-digit increases, with analysts suggesting that AI stocks may offer better long-term returns. The recent surge in PTHL's stock price indicates a moderate influence on market sentiment and potential financial performance.
6 Sep
Pheton Holdings Ltd closed its initial public offering of 2,250,000 Class A ordinary shares at $4.00 per share, raising $9 million. The Company's shares began trading on the Nasdaq Capital Market under the symbol 'PTHL'. The successful completion of the IPO and trading of shares on Nasdaq is expected to have a significant impact on Pheton Holdings Ltd's future performance and market trajectory.
5 Sep
Pheton Holdings Ltd announced pricing of its initial public offering of 2,250,000 Class A ordinary shares at $4.00 per share, with total gross proceeds of $9 million. The shares are expected to begin trading on Nasdaq under the ticker symbol 'PTHL.' The pricing of the IPO and potential listing on Nasdaq are significant events that could impact Pheton Holdings Ltd's future trajectory and investor sentiment.